Indian patent practice and jurisprudence with respect to biological materials (including antibodies) is relatively new and thus not well-settled and/or uniform, unlike in the USA or Europe. In these circumstances, presenting a concrete picture re patenting of monoclonal antibodies in India is not feasible at this stage. Notwithstanding this constraint, this analysis presents various techno-legal...Read More